Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Skyliv-L is a hepatoprotective combination therapy marketed by Skyways Healthcare as a liver tonic. It typically contains L-ornithine L-aspartate and silymarin. L-ornithine L-aspartate facilitates the detoxification of ammonia by stimulating the urea cycle and glutamine synthesis, which is particularly beneficial in managing hepatic encephalopathy. Silymarin, a flavonolignan complex derived from milk thistle (Silybum marianum), provides antioxidant effects, stabilizes hepatocyte membranes, and promotes liver regeneration by stimulating protein synthesis. The product is indicated for the treatment of various liver conditions, including fatty liver, hepatitis, and cirrhosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Skyliv-L.